PMC9097221_01
Daily average activity scores collected via an activity monitoring collar (PetPace) from a 14-year-old dog suffering from bilateral hip and elbow osteoarthritis and severe neck pain, before and after liposomal cannabidiol (CBD) subcutaneous injection. X-axis represents days before (negative) and after (positive) liposomal CBD injection on day 0.
fvets-09-892306-g0001.jpg
PMC9097221_01_fvets-09-892306-g0001.jpg
F1
Daily average activity data collected by the collar is presented in Figure 1. Thereafter he recovered gradually, and had improved owner and iVAS pain scores, and increased collar activity scores (compared to his activity before the injection) up to 3 weeks following injection (Table 1, Figure 1).
Plasma cannabidiol (CBD) concentrations (ng/mL) in a 14-year-old dog suffering from bilateral hip and elbow osteoarthritis and severe neck pain. The arrows indicate subcutaneous liposomal CBD injections that were performed on days 0 (5 mg/kg) and 28 (3 mg/kg).
fvets-09-892306-g0002.jpg
PMC9097221_01_fvets-09-892306-g0002.jpg
F2
Blood (1-2 mL) was also collected for pharmacokinetic analysis at 2, 4, and 6 h, daily at 1-6 days, 8-, 10-, 14-, 17-, 21-, 25-, and 28-days following injection (Figure 2). The improvement in the pain score correlated with the pharmacokinetic profile obtained (Figure 2). Blood samples were collected for pharmacokinetic analysis at 2 and 6 h, and 1 day following injection (Figure 2).